169 related articles for article (PubMed ID: 32336065)
41. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Sakata S; Otsubo K; Yoshida H; Ito K; Nakamura A; Teraoka S; Matsumoto N; Shiraishi Y; Haratani K; Tamiya M; Ikeda S; Miura S; Tanizaki J; Omori S; Yoshioka H; Hata A; Yamamoto N; Nakagawa K
Cancer Sci; 2022 Jan; 113(1):221-228. PubMed ID: 34704312
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
43. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.
Sholl LM; Aisner DL; Varella-Garcia M; Berry LD; Dias-Santagata D; Wistuba II; Chen H; Fujimoto J; Kugler K; Franklin WA; Iafrate AJ; Ladanyi M; Kris MG; Johnson BE; Bunn PA; Minna JD; Kwiatkowski DJ;
J Thorac Oncol; 2015 May; 10(5):768-777. PubMed ID: 25738220
[TBL] [Abstract][Full Text] [Related]
44. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
45. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
Deng H; Liu C; Zhang G; Wang X; Liu Y
Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
[TBL] [Abstract][Full Text] [Related]
46. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
[TBL] [Abstract][Full Text] [Related]
47. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
48. Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer.
Jia X; Zhang L; Wu W; Zhang W; Wu C
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):246-253. PubMed ID: 27438512
[TBL] [Abstract][Full Text] [Related]
49. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
50. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
51. Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.
Wang Q; Lv Y; Zhong M; Zhu F; Wei L; Shi H
J BUON; 2017; 22(4):1053-1060. PubMed ID: 28952227
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
[TBL] [Abstract][Full Text] [Related]
53. Developing a New qPCR-Based System for Screening Mutation.
Zhu J; Zhao Y; Liu M; Gonzalez-Rivas D; Xu X; Cai W; Qi H; Dai L; Wang Z; Song X; Jiang G; Yang Y
Small; 2019 Mar; 15(9):e1805285. PubMed ID: 30677225
[TBL] [Abstract][Full Text] [Related]
54. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
55. Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology.
Tanaka R; Sakamoto N; Suzuki H; Tachibana K; Ohtsuka K; Kishimoto K; Fujiwara M; Kamma H; Shibahara J; Kondo H
Diagn Cytopathol; 2019 Jun; 47(6):564-570. PubMed ID: 30741488
[TBL] [Abstract][Full Text] [Related]
56. Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy.
Kim HK; Lee HY; Choi YL; Choi SJ; Choi H; Lee J; Han J; Ahn MJ; Lee KS; Kim J
Anticancer Res; 2014 Feb; 34(2):707-14. PubMed ID: 24511003
[TBL] [Abstract][Full Text] [Related]
57. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
58. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
59. ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing.
Kheng YC; Walsh K; Williams L; Wallace WA; Harrison DJ; Oniscu A
J R Coll Physicians Edinb; 2018 Mar; 48(1):20-24. PubMed ID: 29741520
[TBL] [Abstract][Full Text] [Related]
60. Somatic mutations and immune checkpoint biomarkers.
Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]